ARCHIVES

Tafinlar Subgroup Data Shows Median OS of 20 Months

This article is from The Cancer Letter archive.

Vol. 37 No. 10 | October 31, 2014

Download PDF Visit The Full Archive

Related Articles

First-Line Tarceva Nearly Doubles PFS in EGFR-Activated Tumors

June 24, 2011

Supreme Court Decision Means FTC Scrutiny As Costly Oncology Drugs Go Off-Patent

June 21, 2013

FDA News: FDA Grants Accelerated Approval to Mekinist-Tafinlar Combination

January 10, 2014

In Brief: Susan O’Brien to move to UC Irvine Health

November 14, 2014

Chemo Combinations Tested In Phase III For Lung Cancer

August 31, 2001

In Brief: Jack McShulkis Dies Following Stroke; Congress Gives Final Approval to Appropriations Bill

October 28, 1983